Background: The detection of driver aberrations such as EGFR and ALK, in tumour tissue or plasma has become important for treating lung cancer patients. The aim of this study is to explore the feasibility of detecting therapy-guiding aberrations in RNA, isolated from platelet and plasma samples. Conclusions: In conclusion, the fraction of tumour-derived RNA transcripts in plasma and platelets appears to be very low or undetectable. Our data indicates that plasma and platelet-derived RNA is not a good source to identify tumour cell specific genomic aberrations. READ ARTICLE
Annals of Oncology DOI:10.1093/annonc/mdz413.025
Authors: P. Meng, A. A. Rybczynska, J. Wei, M. M. Terpstra, W. Timens, E. Schuuring, T. J. N. Hiltermann, H. J. M. Groen, K. Kok, A. J. Van der Wekken, A. Van den Berg